Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib in Advanced Chordoma
NCT06140732Phase 2Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Oct 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in chordoma, sponsored by Xuanwu Hospital. Started Oct 2023; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
chordoma
Beyond the preview
Go deeper on NCT06140732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06140732.